The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | The role of transfusion support in older patients with AML no longer receiving active therapy
In this video, Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the role of transfusion support in older patients with newly diagnosed acute myeloid leukemia (AML) who are no longer receiving active therapy, highlighting the continued value of red blood cell transfusions for improving quality of life and symptom control, while noting the less clear benefit of platelet transfusions in this setting. Dr Lancet emphasizes that transfusion support should be utilized as long as patients derive clinical benefit, but can be discontinued once this is no longer the case. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, one of the problems with AML compared to other cancers is that there is a severe anemia and thrombocytopenia problem that affects quality of life and length of life, we think. And in patients that are no longer receiving active therapy, there is still benefit to receiving supportive care in the form of transfusions. And the recommendations are pointing towards the continued role of red blood cell transfusion support in such patients, but the role of platelet support is a little bit less clear in this setting based on a relative lack of data to really understand exactly what that is being used to help patients achieve better outcomes...
Well, one of the problems with AML compared to other cancers is that there is a severe anemia and thrombocytopenia problem that affects quality of life and length of life, we think. And in patients that are no longer receiving active therapy, there is still benefit to receiving supportive care in the form of transfusions. And the recommendations are pointing towards the continued role of red blood cell transfusion support in such patients, but the role of platelet support is a little bit less clear in this setting based on a relative lack of data to really understand exactly what that is being used to help patients achieve better outcomes. So in general, there is still a role of transfusion support for such patients who are no longer receiving active therapy, as long as they are benefiting clinically in terms of symptom control, quality of life, but that when it comes to transfusions in patients who are no longer deriving any clinical benefit, it certainly can be discontinued in that setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
